Poster Numbers

P01 *The next generation of covalent fragments: sulfur(VI) fluoride warheads for ligandability assessments and hit identification*

 **Arron Aatkar**, University of Strathclyde / GlaxoSmithKline, UK

P02 *Medicinal and biological chemistry of polyamines and their conjugates*

 **Abdulaziz Al Khzem**, University of Bath, UK

P03 *Novel anti-tubulin compounds from Trigonella Foenum-Graecum seeds: insights into* in-vitro*, and molecular docking studies*

 **Norah Aljammaz**, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia

P04 *Design, synthesis and evaluation of pyrazolo[3,4-d]pyrimidine kinase inhibitors for glioblastoma*

 **Daniel Baillache**, CRUK Edinburgh Centre, University of Edinburgh, UK

P05 *Fragment library screening by Grating Coupling Interferometry (GCI) and benefits over Surface Plasmon Resonance (SPR)*

 **Ray Boffey**, Domainex Ltd, UK

P06 *Biological evaluation of carnosine analogues*

 **Klaudia Chmielewska**, Gdansk University of Technology, Poland

P07 *Glucuronide metabolites, why bother?*

 **Liam Evans**, Hypha Discovery Limited, UK

P08 In situ *click chemistry applied to bunyavirales: from conventional drug design to enzymes assembling their own inhibitors*

 **Laura Garlatti**, AFMB CNRS, France

P09 *Kinetic evaluation of sulfur(VI) fluoride reactive functionalities to enable the rapid development of therapeutics*

**Katharine Gilbert**, University of Strathclyde / GlaxoSmithKline, UK

P10 *A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis*

 **Daniel Harris**, University of Glasgow, UK

P11 *An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)*

**Islam Khawaldeh**, Cancer Research UK, Newcastle University, UK

P12 *Emerging synthetic technologies in fragment-based drug discovery*

 **Tim Kwok**, Astex Pharmaceuticals, UK

P13 *Fragment-to-lead discovery of a potent series of 2-aminooxazole carboxamide inhibitors of human PAICS*

 **Jon Large**, LifeArc, UK

P14 *A novel highly efficient thiol-selective bioconjugation for the preparation of drug conjugates*

 **Melinda Morelli**, Durham University, UK

P15 *Characterisation of pharmaceutical formulations using Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS)*

 **Niamh O'Mahoney**, University College Cork, Ireland

P16 *Development ofinhibitors for DNA gyrase as novel antibacterials*

 **Kyle Orritt**, University of Leeds, UK

P17 *Macrolide inspired macrocycles as modulators of the IL-17A/IL-17RA interaction*

 **Dijana Pešić**, Fidelta Ltd, Croatia

P18 *Exploiting the biophysical sweet spot in fragment-based drug discovery*

 **Thomas Pesnot**, Concept Life Sciences, UK

P19 *Analogues of methyllycaconitine and lappaconitine*

 **Ashraf Qasem**, University of Bath, UK

P20 *Exploiting automated R group core and table generation From matched molecular pair data to accelerate SARS-CoV2 therapeutic discovery*

**Lauren Reid**, MedChemica Ltd, UK

P21 *Structure-based optimisation of a potent class of isoindolinone inhibitors of the MDM2-p53 protein-protein interaction*

**François Saint-Dizier**, Astex Pharmaceuticals UK

P22 *Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)*

**Wolfgang Schmidt**, Charles River Laboratories, UK

P23 *Phenothiazine based small molecule as nanomolar 20S proteasome activator*

 **Sophia Staerz**, Michigan State University, USA

P24 *Accelerating lead optimization with AI-assisted generative design and scaffold hopping*

 **Istvan Szabo**, ChemPass Ltd, Hungary

P25 *High-throughput synthesis of PhotoAffinity Bits (PhABits) to study protein-ligand binding*

 **Ross Thomas**, University of Strathclyde / GlaxoSmithKline, UK

P26 *C–H functionalisation tolerant to polar groups could transform FBDD*

 **Chloe Townley**, Astex Pharmaceuticals, UK

P27 In vitro *anticancer activity of urease mimetic Cobalt(III) complexes on A549- lung cancer cells*

 **Bhawna Uprety**, University of Johannesburg, South Africa

P28 *Development of a new native mass spectrometry platform for identifying protein-protein interaction inhibitors*

 **Clinton Veale**, University of KwaZulu-Natal, South Africa

P29 *S6K1 inhibitors for fragile X syndrome and triple negative breast cancer*

 **David Walker**, Sentinel Oncology Ltd, UK

P30 *Metabolites profiling,* in vitro, in vivo, *computational pharmacokinetics and biological predictions of aloe perryi resins methanolic extract*

 **Khawla Kahtani**, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia